Kevin is an Engineering Fellow with Lilly’s Synthetic Molecule Design and Development organization in Indianapolis, Indiana. He has worked on the process development and optimization of many early as well as late phase products and led the technology transfer, validation, and launch of several marketed compounds. Kevin has also led initiatives for developing enhanced filings in support of the ICH Q8, Q9, Q10 and Q11 guidelines. Most recently, Kevin is responsible for the engineering design and implementation of Lilly’s synthetic peptide development facility. He has worked closely with an expert team to implement a strategy for synthesizing peptides using a standardized manufacturing platform and applying the strategy to Lilly’s growing peptide portfolio. Kevin also leads the late phase development team responsible for the commercialization of Lilly’s latest phase peptide asset.